Randomised, Double-blind Study to Investigate the Safety and Efficacy of Brotizolam in Insomnia Outpatients.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00347295
Recruitment Status : Completed
First Posted : July 4, 2006
Last Update Posted : December 28, 2017
Information provided by:
Boehringer Ingelheim

June 30, 2006
July 4, 2006
December 28, 2017
June 2006
January 2007   (Final data collection date for primary outcome measure)
change of Sleeping Dysfunction Rating Scale (SDRS) total score of Brotizolam in comparison with Estazolam after a 14-day oral administration in patients with insomnia.
Same as current
Complete list of historical versions of study NCT00347295 on Archive Site
The Clinical Global Impression- Improvement score(CGI-I) The Clinical Global Impression- Severity score (CGI-S) Effective rate Rebound phenomena
Same as current
Not Provided
Not Provided
Randomised, Double-blind Study to Investigate the Safety and Efficacy of Brotizolam in Insomnia Outpatients.
A Randomised, Double-blinded, Double-dummy, Multi-center, Paralleled Study to Investigate the Safety and Efficacy of Brotizolam (Lendormin) Compared With Estazolam in Insomnia Outpatients.
To investigate the efficacy and safety of Brotizolam in the treatment of patients with insomnia in comparison with that of Estazolam

It is intended to recruit 240 insomnia outpatients in this study, 120 patients receiving Brotizolam + Estazolam placebo (Test Group) and 120 patients given Estazolam + Brotizolam placebo (Control Group).

Study Hypothesis:

Brotizolam can be safely used in insomnia patients in China. And Brotizolam 0.25mg is non-inferior with Estazolam 1-2mg in treatment of insomnia patients in China


Estazolam 1-2mg

Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Sleep Initiation and Maintenance Disorders
  • Drug: Brotizolam
  • Drug: Estazolam
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
January 2007
January 2007   (Final data collection date for primary outcome measure)


Patients will be eligible for enrollment of this study if they meet all of the following criteria:

  • Willing and able to provide written informed consent
  • Male or female, aged 18 - 65 (including 18 and 65)
  • Diagnosed as insomnia by the criteria of CCMD-3:


  • Who received any central nervous system drugs within one week before visit 2(baseline)
  • Continuous use of hypnotic agents for more than 3 months recently
  • History of inefficiency with benzodiazepine-type hypnotics
  • Who have a history of obvious hypersensitivity
  • Hamilton Depression Rating Scale (HAMD)18
  • Who was diagnosed with other mental illness
  • With serious diseases of heart, liver and kidney, etc
  • Who had sleep apnoea syndrome
  • Who had epileptic seizures within one year
  • With angle closure glaucoma that is acute or easy to occurred
  • Whose AST or ALT values are 2 times of normal upper limit
  • Whose Cr or BUN values are 2 times of normal upper limit
  • Who are known to be prone to the abuse of alcohol (i.e. history of evidence of acute or chronic abuse), or any other addictive agents
  • Who is participating in other clinical trial, or have participated in a clinical study of any other drug in one month prior to visit 2 (baseline). In addition, patients who has been randomized in this trial and then withdrew can not be enrolled again.
  • All pregnant, lactational women and women who have the plan of pregnancy.
  • Who are unwilling to or not able to complete the whole clinical trial
  • Other patients who are unsuitable to be included in the trial judged by investigator
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
Not Provided
Boehringer Ingelheim
Not Provided
Study Chair: Boehringer Ingelheim Study Coordinator Boehringer Ingelheim Shanghai
Boehringer Ingelheim
December 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP